Recursion Pharmaceuticals (RXRX) EBT: 2020-2025
Historic EBT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$162.2 million.
- Recursion Pharmaceuticals' EBT fell 69.58% to -$162.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.7 million, marking a year-over-year decrease of 86.89%. This contributed to the annual value of -$464.8 million for FY2024, which is 39.94% down from last year.
- Latest data reveals that Recursion Pharmaceuticals reported EBT of -$162.2 million as of Q3 2025, which was up 5.61% from -$171.9 million recorded in Q2 2025.
- Over the past 5 years, Recursion Pharmaceuticals' EBT peaked at -$30.5 million during Q1 2021, and registered a low of -$202.6 million during Q1 2025.
- Over the past 3 years, Recursion Pharmaceuticals' median EBT value was -$97.1 million (recorded in 2023), while the average stood at -$121.2 million.
- As far as peak fluctuations go, Recursion Pharmaceuticals' EBT crashed by 153.94% in 2021, and later grew by 6.12% in 2022.
- Recursion Pharmaceuticals' EBT (Quarterly) stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then plummeted by 59.16% to -$97.1 million in 2023, then crashed by 84.32% to -$178.9 million in 2024, then crashed by 69.58% to -$162.2 million in 2025.
- Its EBT stands at -$162.2 million for Q3 2025, versus -$171.9 million for Q2 2025 and -$202.6 million for Q1 2025.